ALGEN fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
genOway SA engages in the development of genetically modified mouse, rat, and cellular models for biopharmaceutical and research companies. Its technologies include CRISPR/Cas9, homologous recombination (HR), site-specific recombination (SSR), internal ribosome entry sites (IRES), and tetracycline (TET). The company was founded by Alexandre Fraichard and Gilles de Poncins on March 1, 1999, and is headquartered in Lyon, France.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
ALGEN does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company